Hospital Universitario Marques De Valdecilla
- Address
- Avenida Valdecilla Sn, 39008 Santander, Spain
Oncology and Solid Tumors
At Hospital Universitario Marques De Valdecilla, oncology research is heavily focused on a wide range of cancers, especially advanced and metastatic disease. Studies here are exploring new ways to improve treatment effectiveness, extend survival, and better control disease progression across multiple tumor types.
- Advanced non-small cell lung cancer, colorectal cancer, gastric cancer, and pancreatic cancer
- Breast cancer, including HER2-positive, hormone receptor-positive, and triple-negative disease
- Melanoma, head and neck cancer, urothelial cancer, and other solid tumors
Many of these trials are testing new anticancer therapies or combinations designed to improve responses in patients with hard-to-treat or previously treated cancers.
Hematology and Blood Cancers
The site has a strong program in hematologic malignancies, covering both newly diagnosed and relapsed disease. Research is centered on finding more effective treatments for blood cancers and improving long-term disease control.
- Multiple myeloma and plasma cell disorders
- Diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma
- Acute leukemia, including acute lymphoblastic leukemia and acute myeloid leukemia
These studies often aim to improve response rates, deepen remission, and support better outcomes for patients with difficult-to-treat blood cancers.
Gastroenterology and Liver Disease
Clinical trials in digestive system diseases and hepatology include both cancer and non-cancer conditions. The research is addressing chronic liver injury, inflammatory bowel disease, and acute digestive disorders.
- Non-alcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, and cirrhosis
- Hepatitis B, hepatitis C, and other chronic viral liver infections
- Ulcerative colitis, Crohn’s disease, and acute pancreatitis
The main goals include testing new treatments, improving disease control, and reducing complications in liver and gastrointestinal disorders.
Cardiovascular and Metabolic Research
The site also supports broad research in cardiovascular disease, diabetes, and related metabolic conditions. These trials are designed to lower risk, prevent complications, and improve long-term health in high-risk patients.
- Acute myocardial infarction, atherosclerotic cardiovascular disease, and heart valve disease
- Type 2 diabetes, obesity, and overweight
- Venous thromboembolism, hypertension, and aortic stenosis
Research in this area is often focused on evaluating better prevention strategies and treatment approaches for common but serious cardiometabolic conditions.
Respiratory, Autoimmune, and Inflammatory Diseases
Hospital Universitario Marques De Valdecilla is also active in trials for chronic lung disease, autoimmune disorders, and systemic inflammatory conditions. These studies reflect a strong interest in improving symptom control and reducing flare-ups and organ damage.
- Asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis
- Rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus
- Systemic sclerosis, Sjögren’s syndrome, and vasculitis
The purpose of these trials is to test new therapies that may better control inflammation, preserve function, and improve quality of life for patients with chronic immune-mediated disease.
Transplantation, Infections, and Supportive Care
The research portfolio includes important studies in transplant medicine, infectious diseases, and supportive care for patients with complex medical needs. These trials aim to prevent complications and improve recovery after intensive treatment.
- Graft-versus-host disease, including acute and chronic forms
- Cytomegalovirus infection, fungal infections, and serious bacterial infections
- Lung transplant and other post-transplant infection prevention strategies
This area of research is focused on better prevention, safer supportive care, and improved outcomes for patients undergoing cell therapy or transplantation.
Neurology, Psychiatry, and Rare Diseases
The trial landscape also extends into neurological disease, mental health, and selected rare conditions. These studies are exploring ways to slow progression, improve symptoms, and support better daily functioning.
- Alzheimer’s disease and Parkinson’s disease
- Migraine and other chronic headache disorders
- Rare metabolic, genetic, and immune disorders
The main research purpose is to evaluate new treatments and better understand disease mechanisms in conditions where current options remain limited.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 35 therapeutic areas and 15 of 682 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 640 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 138 by active trials.
- 1AstraZeneca AB19active
lock +137 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB45trials
lock +94 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario Marques De Valdecilla
lock Showing 1 of 611 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 682 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 45 | Unknown | 2018-08-24 | 2026-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
